By Fineline Cube 
iRegene Therapeutics Co., Ltd. announced the successful completion of RMB 260 million (approximately USD 36 million) in Series C+ financing, led by Chengdu Science and Technology Innovation Investment Group with participation from major institutional investors including China Securities Co., Ltd. Investment, Wuxi Venture Capital Group, Dingtaixing, Xinjiye, and Hony Capital. Existing shareholders Yuanxi Haihe and Jinshajiang United Runpu Yuanfeng also made additional investments, demonstrating continued confidence in the company’s regenerative medicine pipeline.
Financing Details
| Parameter | Detail |
|---|---|
| Amount Raised | RMB 260 million (USD 36 million) |
| Round | Series C+ |
| Lead Investor | Chengdu Science and Technology Innovation Investment Group |
| New Investors | China Securities Co., Ltd. Investment, Wuxi Venture Capital Group, Dingtaixing, Xinjiye, Hony Capital |
| Participating Existing Shareholders | Yuanxi Haihe, Jinshajiang United Runpu Yuanfeng |
| Primary Use of Proceeds | Clinical development of NouvNeu001 and pipeline expansion |
Lead Product: NouvNeu001 for Parkinson’s Disease
Product Profile
- Therapy Type: Off-the-shelf (universal) iPSC-derived dopaminergic neural precursor cell therapy
- Indication: Parkinson’s disease
- Development Status: Simultaneous clinical trials in China and the United States
- Regulatory Designations:
- FDA Fast Track designation
- Regenerative Medicine Advanced Therapy (RMAT) designation
Competitive Advantages
- Universal Donor Platform: Eliminates need for patient-specific cell manufacturing
- Scalable Manufacturing: iPSC platform enables consistent, large-scale production
- Regulatory Acceleration: Dual FDA designations provide expedited development pathways
- Global Development Strategy: Parallel trials in US and China maximize market access potential
Pipeline Portfolio Beyond Parkinson’s Disease
| Candidate | Indication | Stage | Differentiation |
|---|---|---|---|
| NouvNeu004 | Multiple System Atrophy (MSA) | Preclinical/IND-enabling | Extension of neural precursor platform to related neurodegenerative disorder |
| NouvSight Series | Ophthalmic diseases | Early development | Application of iPSC technology to retinal and ocular conditions |
Market Opportunity & Strategic Context
- Parkinson’s Disease Burden: Affects over 10 million people globally, with no disease-modifying therapies currently available
- Cell Therapy Market: Regenerative medicine sector projected to exceed $100 billion by 2030, with neurological applications representing high-value segment
- Chinese Biotech Ecosystem: Strong government support for innovative cell and gene therapy development through national strategic initiatives
- Investment Climate: Continued institutional appetite for late-stage biotech despite broader market volatility, particularly for assets with US regulatory validation
Strategic Implications
- Clinical Milestone Funding: Capital positions iRegene to achieve key clinical readouts for NouvNeu001 in both US and Chinese trials
- Manufacturing Scale-Up: Resources allocated to GMP facility expansion and process optimization for commercial readiness
- Pipeline Acceleration: Enables parallel advancement of NouvNeu004 and NouvSight programs into clinical development
- Global Partnership Potential: Strong regulatory designations and clinical data could attract international pharma collaboration interest
- Exit Strategy Enhancement: Dual-market development de-risks commercial prospects and increases valuation multiples
The Series C+ financing round underscores investor confidence in iRegene’s iPSC-derived cell therapy platform and validates the significant unmet medical need in Parkinson’s disease treatment, positioning the company as a leading player in the global regenerative medicine landscape.-Fineline Info & Tech